Abstract
Objective: To develop a systematic set of German cost data in rheumatoid arthritis (RA) based solely on valid healthcare payer's cost data sources.
Methods: Retrospectively one year cost data of 338 patients with RA were generated and analysed. The cost data were derived from a major statutory health insurance plan ("Allgemeine Ortskrankenkasse Niedersachsen") and the regional physicians' association ("Kassenärztliche Vereinigung Niedersachsen"). The recently published matrix of cost domains in RA was applied to structure the analysis. Descriptive statistics were used to analyse the data.
Results: The total direct costs for the 338 patients during one year (third quarter 2000 to second quarter 2001) were €3815 per patient-year. RA related direct costs were €2312 per patient-year. Outpatient costs accounted for 73.7%, inpatient costs for 24.0%, and other disease related costs for 2.3% of RA related direct costs. Outpatients cost drivers were RA related drugs (€1019 per patient-year), physician visits (€323 per patient-year), diagnostic and therapeutic procedures and tests (€185 per patient-year), and devices and aids (€168 per patient-year). 98 patients were retired prematurely owing to RA related work disability and incurred costs of €8358 per retired patient-year. 96 patients were gainfully employed and incurred sick leave costs of €2835 per employed patient-year.
Conclusion: Micro-costing based on healthcare payer's data provides a relatively conservative albeit highly accurate estimate of costs in RA. Both RA related and non-RA related costs must be taken into account. In gainfully employed patients and in patients who receive RA related retirement payments productivity costs exceed direct costs.
Full Text
The Full Text of this article is available as a PDF (154.2 KB).
Figure 1.
Development of RA related drug costs (without gastroprotective drugs) over the course of one year.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Clarke A. E., Zowall H., Levinton C., Assimakopoulos H., Sibley J. T., Haga M., Shiroky J., Neville C., Lubeck D. P., Grover S. A. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol. 1997 Jun;24(6):1051–1060. [PubMed] [Google Scholar]
- Kobelt G., Eberhardt K., Jönsson L., Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999 Feb;42(2):347–356. doi: 10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
- Merkesdal S., Ruof J., Mittendorf T., Mau W., Zeidler H. Gesundheitsökonomische Forschung im Bereich der chronischen Polyarthritis. Z Rheumatol. 2002 Feb;61(1):21–29. doi: 10.1007/s003930200003. [DOI] [PubMed] [Google Scholar]
- Merkesdal S., Ruof J., Schöffski O., Bernitt K., Zeidler H., Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 2001 Mar;44(3):528–534. doi: 10.1002/1529-0131(200103)44:3<528::AID-ANR100>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
- Ruof J., Hülsemann J. L., Stucki G. Evaluation of costs in rheumatic diseases: a literature review. Curr Opin Rheumatol. 1999 Mar;11(2):104–109. doi: 10.1097/00002281-199903000-00004. [DOI] [PubMed] [Google Scholar]
- Yelin E., Wanke L. A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999 Jun;42(6):1209–1218. doi: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]